Composite end points in clinical trials

JAMA

Volumn 303, Issue 17, 2010, Pages 1698-

  Sheehe, Paul R ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

CLINICAL RESEARCH; CLINICAL TRIAL; DIABETES MELLITUS; EVENT FREE SURVIVAL; HUMAN; LETTER; LIFE EVENT; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; BIOASSAY; KAPLAN MEIER METHOD; NOTE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL;

ENDPOINT DETERMINATION; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIERS ESTIMATE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES;

EID: 77951890221     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.523     Document Type: Letter

References (3)

1. Tomlinson G, Detsky AS. Composite end points in randomized trials: there is no free lunch. JAMA. 2010;303(3):267-268.
2. Gerstein HC, Yusuf S, Bosch J, et al; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368:1096-1105.
3. Breslow NE. Contribution to the discussion of paper by D. R. Cox. J R Stat Soc B. 1972;34:216-217.